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Tumor initiation and metastasis formation in many cancers have been 
associated with emergence of a gene expression program normally active in 
embryonic or organ-specific stem cells. In particular, the stem cell transcription 
factor Sox2 is not only expressed in a variety of tumors, but is also required for 
their formation. Melanoma, the most aggressive skin tumor, derives from 
melanocytes that during development originate from neural crest stem cells. 
While neural crest stem cells do not express Sox2, expression of this 
transcription factor has been reported in melanoma. However, the role of Sox2 
in melanoma is controversial. To study the requirement of Sox2 for melanoma 
formation, we therefore performed CRISPR-Cas-mediated gene inactivation in 
human melanoma cells. In addition, we conditionally inactivated Sox2 in a 
genetically engineered mouse model, in which melanoma spontaneously 
develops in the context of an intact stroma and immune system. Surprisingly, in 
both models, loss of Sox2 did neither affect melanoma initiation, nor growth, nor 
metastasis formation. The lack of a tumorigenic role of Sox2 in melanoma might 
reflect a distinct stem cell program active in neural crest stem cells and during 
melanoma formation. 
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INTRODUCTION 
The transcription factor Sox2 plays a crucial role during embryogenesis and is 
necessary for proper development of multiple cell types1,2. It controls pluripotency in 
embryonic stem cells and is one of the four originally described factors required for 
reprogramming of differentiated cells into induced pluripotent stem cells3,4. Sox2 has 
been extensively studied in the central nervous system, where it regulates 
maintenance of stem and progenitor cells5–8. Likewise, in adult mouse tissue, Sox2 
marks epithelial stem cells in various tissues of endodermal and ectodermal origin and 
is required for their homeostasis9. Moreover, conditional deletion of Sox2 impaired 
osteoblast proliferation and resulted in aberrant bone formation further highlighting the 
role of this transcription factor in a broad range of normal stem and progenitor cells10. 
 
Sox2 has also been implicated in controlling stem cell activity in a variety of tumors1. 
Indeed, genetic lineage tracing in medulloblastoma and squamous cell carcinoma 
(SCC), respectively, demonstrated that Sox2 is expressed in cancer stem cells in vivo, 
i.e. in cells associated with tumor initiation and propagation11,12. Consistent with these 
data, Sox2 ablation in a SCC mouse model led to decreased tumor formation12. More 
recently, Sox2 was revealed by overexpression experiments in genetically engineered 
mouse models to be a driver of lung SCC13. Sox2 was also shown to be critical for the 
initiation of pituitary gland tumors upon loss of the tumor suppressor p27 or of the 
retinoblastoma tumor suppressor gene Rb14,15. Similarly, Sox2 was required for tumor 
initiation by murine oligodendroglioma cells and by human glioblastoma cells 
transplanted into appropriate mouse model systems, in agreement with the reported 
role of Sox2 in maintaining glioma-initiating cells16–18. The combined data indicate a 
tumorigenic role of Sox2 in many cancers. In contrast, Sox2 appears to act as a tumor 
suppressor gene in gastric tumors driven by canonical Wnt signal activation, pointing 
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to context-dependent activities of Sox2 in regulating cell proliferation and 
tumorigenesis19. 
 
In melanoma, the function of Sox2 is controversial. Tissue microarray (TMA) 
expression analysis revealed that SOX2 protein is expressed in around 50% of all 
human melanoma20,21. In a recent study, RNAi-mediated silencing of SOX2 led to 
reduced melanoma sphere self-renewal and tumor growth of xenotransplanted cells, 
supporting an important role of Sox2 in tumor initiation and tumor maintenance22. In 
other reports, however, knockdown of SOX2 did not affect proliferation of human 
melanoma cells20,21,23. Instead, SOX2 knockdown cells displayed reduced 
invasiveness, whereas SOX2 overexpression increased the invasion capacity of 
human melanoma cells23. In agreement with this, SOX2 was recently shown to mediate 
TGF-induced invasion in human melanoma cells24. Thus, at least in isolated 
melanoma cells, SOX2 has been implicated in either growth control or invasiveness, 
but its function in vivo remains to be elucidated.  
 
To shed light on this issue, we decided to analyse the role of Sox2 during melanoma 
oncogenesis using knockout approaches that fully block Sox2 function and, in 
particular, using a genetically engineered mouse melanoma model, in which metastatic 
melanoma spontaneously develops within an intact stromal environment25,26. However, 
conditional Sox2 inactivation did not affect tumor initiation and progression, speaking 
against an essential function for this transcription factor in melanoma. 
 
 
RESULTS AND DISCUSSION 
SOX2 expression is not linked to patient survival 
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To address the potential relevance of SOX2 for melanoma in human patients, we first 
interrogated RNA sequencing (RNA-seq) and clinical data from The Cancer Genome 
Atlas (TCGA) and cBioPortal 27,28. To compare SOX2 expression levels in cutaneous 
melanoma with those in other cancers, we plotted the three cancers with the lowest 
expression (acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBC), 
chromophobe renal cell carcinoma (chRCC)) and the highest expression (lung 
squamous cell carcinoma (SCC), glioblastoma multiforme (GBM), lower grade (diffuse) 
gliomas). Additionally, we analysed SOX2 expression in the three most frequently 
diagnosed cancers (colorectal (CRC), breast and lung cancer). Cutaneous melanoma 
showed low expression levels compared to the three cancers highly expressing the 
transcription factor (Figure 1a). Next, we analysed whether SOX2 expression was 
changed based on the location of the biopsy or stage of the tumor, comparing primary 
melanoma, skin metastasis, lymph node metastasis, and distant metastasis. However, 
we did not observe significant changes in SOX2 expression at different stages of 
disease progression (Figure 1b). Breslow depth, which is defined as the total vertical 
height of the tumor, is one major important prognostic predictor of death from 
melanoma29,30. Therefore, we plotted SOX2 expression from human primary 
melanomas to Breslow thickness. Again, we could not detect any correlation between 
SOX2 expression and Breslow thickness (Figure 1c). Finally, we analysed RNA-seq-
based SOX2 expression from 420 melanoma patients and established a SOX2 high 
(top 20%, 79 patients) and a SOX2 low (bottom 20%, 80 patients) patient group (Figure 
1d). Interestingly, patient survival did not correlate with SOX2 expression levels, 
neither when considering overall survival nor when only taking expression in 
metastases into account (Figure 1e, f). Taken together, SOX2 expression is not 
associated with clinical features and disease outcome in patients diagnosed with 
malignant melanoma. 
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SOX2 knockout does not influence tumor growth of human melanoma cells in 
vivo 
So far, a potential requirement of SOX2 for melanoma formation has been addressed 
using RNAi-mediated gene silencing20–23. However, gene knockdown experiments 
reduce gene expression levels only partially and, furthermore, might lead to off-target 
effects, which could have contributed to the reported discrepancies regarding the 
function of SOX2 in melanoma. Therefore, we used the CRISPR-Cas9 technology to 
fully and genetically deplete SOX2 in human melanoma cultures. First, we tested 
several human melanoma cultures for SOX2 protein expression. Only one out of six 
cell culture analyzed (M050829, an NRasQ61L-mutated patient-derived cell line), 
showed strong SOX2 expression, while other cell lines such as the previously used 
A375 and SK-MEL-28 displayed very low SOX2 protein expression (Figure 2a). Given 
these results, we manipulated SOX2 levels of M050829 using the CRISPR-Cas9 
genome editing technology, generating two independent SOX2 knockout (KO) clones 
lacking SOX2 expression (Figure 2b). As controls, we used the original heterogeneous 
cell line. Strikingly, upon xenotransplantation into immunocompromised nude mice, 
both SOX2 KO clones displayed a growth pattern very similar to that of control 
melanoma cells and readily produced tumors in vivo, despite complete depletion of 
Sox2 (Figure 2c, d, e). Thus, SOX2 was not required for melanoma formation and 
growth in our experimental set-up.  
 
 
 
Sox2 is expressed in murine melanoma but not critical for survival time 
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In many cancers other than melanoma, the undisputed role of Sox2 is in tumor 
initiation, potentially reflecting a “de-differentiation” process and emergence of an 
embryonic gene program in cells of tumor origin1,31. Conceivably, such a process 
cannot be adequately assessed in cell lines derived from already established 
metastases, such as those that have been used in previous studies of SOX2 in 
melanoma. Therefore, we sought to address the role of Sox2 in the Tyr::NRasQ61K 
Ink4a-/- mouse model that recapitulates all aspects of melanoma formation, including 
tumor initiation from benign melanocytic cells, primary tumor growth, dissemination of 
metastatic cells, and secondary tumor growth at distant sites 25,26.  
 
First, we monitored expression of Sox2 during disease progression in mice (Figure 3a). 
In normal postnatal mouse skin, Sox2 was expressed in a subset of dermal papillae, 
consistent with previous findings in mouse and human21,32. Further, we did not detect 
Sox2 expression in differentiated Sox10-positive melanocytes located in hair follicle 
bulbs. It has been shown that approximately 50% of human melanomas, but only a 
minority of nevi, express SOX220,21,33. Likewise, Sox2 was only expressed in a small 
subset of Sox10-positive hyperplasia cells of Tyr::NRasQ61K Ink4a-/- mice (mean 3.2%), 
whereas a higher percentage of cells expressed the transcription factor in primary 
tumors (mean 7.9%). The percentage of Sox2/Sox10 double positive cells further 
increased in lymph node metastases (mean 11.2%) (Figures 3a and b).  
 
Based on its expression pattern, Sox2 might promote primary melanoma and 
metastasis formation. To address this question, we performed Tamoxifen (TM)-based 
activation of a melanocyte-specific Cre recombinase (Tyr::CreERT2) in order to induce 
conditional Sox2 ablation in Tyr::NRasQ61K Ink4a-/- mice carrying two floxed alleles of 
Sox2 (Figure 3c)5. Further, we used a Cre-reporter allele (R26R::LacZ) to monitor the 
Schaefer et al.   8 
recombined cells in vivo34. Mice lacking the Tyr::CreERT2 transgene were used as 
controls. To assess if Sox2 has a role in melanoma formation, we conditionally ablated 
the gene before the appearance of primary melanomas by applying TM to 1-month-old 
animals on five consecutive days (Figure 3d). To confirm Sox2 ablation, we co-stained 
three different hyperplasias for R26R::LacZ-mediated β-Galactosidase (β-Gal) and 
Sox2 expression. While in Sox2 conditional knockout (cKO) mice, Sox2 expression 
was never found in β-Gal-positive cells, the transcription factor was expressed in a 
subset of non-recombined, β-Gal-negative cells (Figure 3e). Surprisingly, we did not 
observe a change in melanoma-specific survival between the Sox2 cKO and the 
control group (median survival control: 147 days, median survival Sox2 cKO: 154 days) 
(Figure 3f).  
 
Sox2 is dispensable for primary tumor and metastasis formation 
Tyr::NRasQ61K Ink4a-/- mice reliably develop skin melanoma within 6 months of age and 
often present with metastases in lymph nodes, lungs and liver25,26. Of note, both control 
as well as the Sox2 cKO mice developed a macroscopically visible hyperplasia and 
primary melanomas (Figure 4a, b). Histological analysis of control and Sox2 cKO 
melanomas did not reveal overt changes in the morphological appearance of tumors 
(Figure 4a, b). Moreover, quantification of total skin tumor numbers failed to 
discriminate between the two groups (Figure 4c).  
 
Since in Tyr::NRasQ61K Ink4a-/- mice, TM-induced Tyr::CreERT2 – mediated 
recombination efficiency does usually not reach 100% of all melanocytic cells, primary 
melanoma in Sox2 cKO mice might arise from non-recombined cells36. To exclude this 
possibility, we determined the overall recombination rate (β-Gal-positive/Sox10-
positive cells) in hyperplastic skin and in primary tumors of Sox2 cKO mice, in which 
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Tyr::CreERT2 had been activated at 1 month of age (Figure 3d). Importantly, the 
percentage of recombination in skin tumors (49.0%; n=8) was not significantly altered 
when compared to hyperplastic lesions (50.4%; n=5) (Figure 4d). Thus, loss of Sox2 
neither favored nor prevented contribution of melanocytic cells to growing primary 
melanoma, demonstrating that Sox2 is dispensable for melanoma formation in the 
Tyr::NRasQ61K Ink4a-/- mouse melanoma model.  
 
It has been reported that Sox2 promotes invasiveness in cultured human melanoma 
cells23,24.  Therefore, we also analysed whether deletion of Sox2 in melanoma cells 
affects distant metastasis formation in vivo. However, lung and liver metastases were 
readily detectable in control as well as Sox2 cKO animals (Figure 4e, f, h, i) and the 
total count of lung and liver metastases was not significantly altered upon Sox2 deletion 
(Figure 4g and j). Further, we stained lung metastases for β-Gal and Sox10 to quantify 
the recombination frequency of the metastasized melanoma cells. Again, when 
comparing the recombination frequency in hyperplastic lesions to that in lung 
metastases (mean 52.3%), we could not find any evidence for a positive or negative 
selection of Sox2 cKO cells during formation of distant metastases (Figure 4k and l). 
Hence, melanocyte-specific Sox2 ablation does not affect the capacity of melanoma 
cells to engage in metastasis formation. 
 
In conclusion, our work suggests that the transcription factor SOX2 is not required for 
melanoma formation and progression. Although TMA studies have previously 
confirmed SOX2 expression in a subset of human melanomas20,21, our analysis of 
TCGA data did not reveal any correlation between SOX2 levels and disease outcome. 
Similarly, despite its increasing expression in a fraction of melanoma cells during 
disease progression, Sox2 was dispensable for tumorigenesis and metastasis in a 
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melanoma mouse model. Malignant transformation can result in gain of cellular 
plasticity and loss of differentiation markers. Therefore, we speculate that the 
upregulation of the stem cell factor SOX2 in melanoma cells compared to differentiated 
melanocytes might represent a bystander effect of melanoma cell transformation 
without major functional implications. Alternatively, the lack of phenotype in our study 
might be due to other Sox family members, in particular the SOX2-related factor SOX3, 
compensating for the absence of SOX235. However, such compensation was not 
observed in other tumor types11-18 and we could not find evidence for SOX3 
expression, neither in human SOX2 KO cells nor in murine tumors (data not shown).  
 
Nonetheless, our findings do not rule out that SOX2 can exert certain activities in 
melanoma cells, for instance in isolated cells exposed to varying culture conditions or 
in the non-physiological environment encountered by human cells upon 
xenotransplantation into immunocompromised mouse model systems22. Of note, 
studies performed solely in vitro or in combination with xenotransplantation assays 
provided controversial results, either implicating SOX2 in melanoma cell proliferation 
or invasion, or also failing to reveal a crucial role in melanoma as in our experiments 
performed with CRISPR-Cas-mediated knock out cells20-24. While the discrepancies 
between our work and previously published data could potentially be explained by 
different experimental settings37, they could also reflect the heterogeneity of melanoma 
and, thus, leave open whether SOX2 might fulfill a role in some cases of human 
melanoma. However, we suggest that the pathophysiological role of Sox2 in melanoma 
can best be assessed in genetically engineered mouse melanoma models, in which 
melanoma spontaneously develops within an undisturbed stromal environment and 
without prior tumor cell isolation which might influence the cells’ behavior. Importantly, 
in support of our findings obtained with Tyr::NRasQ61K Ink4a-/- mice, a parallel study 
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performed with Tyr::CreERT2/+; BRafCA/+; Ptenl/l mice38 also demonstrated the 
dispensability of Sox2 for melanoma initiation and growth39. 
 
Cancer formation has been associated with reactivation of embryonic or organ-specific 
stem cell programs40,41. Accordingly, Sox2 has been functionally implicated in several 
tumors emerging from tissues harboring Sox2-positive stem cells1,31. In melanoma, 
tumor-initiating cells have recently been shown to re-express markers of neural crest 
cells, from which melanocytes develop during embryogenesis42. In agreement with this 
finding, inactivation of the neural crest stem cell factor Sox10 counteracts melanoma 
formation in vitro and in vivo25. Unlike the transcription factor Sox10, however, Sox2 is 
not expressed in migratory neural crest stem cells and, at early stages of development, 
actually suppresses neural crest induction and formation of neural crest stem cells from 
neural plate cells43. Thus, the lack of a tumorigenic function of Sox2 described in the 
present study is consistent with the distinct stem cell program active in neural crest 
stem cells and, conceivably, during melanoma formation.  
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Figure 2. SOX2 knockout does not influence tumor growth of human melanoma cells 
in vivo. (a) Human melanoma cells were cultured in RPMI-1640 medium supplemented 
with 10% FCS (16140, Thermo Fisher Scientific), 4mM L-Glutamine (25030, Thermo 
Fisher Scientific), penicillin-streptomycin (15070, Thermo Fisher Scientific) and 
Fungizone Antimycotica (15290, Thermo Fisher Scientific). The cell lines M050829 and 
M070302 have been characterized before44,45. MM150423 was generated at the 
Department of Dermatology of the University Hospital Zurich and approved by the 
ethical committee of the Canton of Zurich, Switzerland. Written informed consent was 
obtained from all subjects and approved by the local institutional review boards (EK647 
and EK800). A375, SK-MEL-28 and WM83 were purchased from ATCC. SOX2 protein 
expression of the human melanoma cell lines was analyzed by Western Blot (1’ 
antibody: sc-17320 (Santa Cruz Biotech, 1:100); 2’ antibody: IRDye 800 CW donkey 
α-goat P/N 925-32214 (LI-COR, 1:10000)). -Actin was used as loading control (1’ 
antibody: 4970 (Sigma, 1:10000) and 2’ antibody: IRDye 680 CW donkey α-rabbit P/N 
925-68072 (LI-COR, 1:10000)). (b) Western Blot analysis of SOX2 protein levels in 
M050829 control cell line, SOX2-CRISPR clone 1 (Cl.1) and SOX2-CRISPR clone 2 
(Cl.2). Following sgRNA sequence was used for CRISPR Cl 1&2: 5’-
GGCCCGCAGCAAACTTCGGGGGG-3’ with a quality score of 87 according to 
http://crispr.mit.edu. (c) 2 month old Foxn1nu/nu female mice were subcutaneously 
engrafted with 150’000 control (black curve), SOX2 CRISPR Cl.1 (red curve), or SOX2 
CRISPR Cl.2 (violet curve) cells (M050829) (n=4 for each condition, non-blinded). 
Tumor volume was measured weekly with a caliper and calculated as follows: V=2/3 x 
π x ((a+b)/4))3, where a (mm) was the length and b (mm) was the width of the tumor. 
1-way ANOVA analysis shows no significant difference between control cells and the 
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two SOX2-CRISPR clones (control vs. CRISPR Cl.1: p=0.47; control vs. CRISPR Cl.2: 
p=0.99).  
 
The sample size was not predetermined by statistical methods. Data is presented as 
mean ± s.e.m. (d) Co- Immunostaining of SOX2 (1’ antibody: ab15830 (abcam, 1:100); 
2’ antibody: Cy3 donkey α-rabbit 711-165-152 (Jackson Immuno Research, 1:300) and 
SOX10 (1’ antibody: sc-17342 (Santa Cruz Biotech 1:100), 2’ antibody: Cy2 Alexa 
Fluor 488 donkey α-goat 704-546-147 (Jackson Immuno Research, 1:300)) on 
paraffin-embedded control, SOX2-CRISPR Cl.1 and SOX2-CRISPR Cl.2 tumors 
(scale bars=50m). (e) Hematoxylin and eosin (H&E) staining showing the morphology 
of xenografted control, SOX2-CRISPR Cl.1 and SOX2-CRISPR Cl.2 cells (scale 
bars=1000m). All animal experiments have been approved by the veterinary 
authorities of Canton Zurich, Switzerland and were performed in accordance with 
Swiss law. 
 
Figure 3. Sox2 is expressed in murine melanoma but not critical for survival. (a) 
Immunostaining on trunk skin sections of wt mice for Sox2 (1’ antibody: ab15830 
(abcam, 1:100), 2’ antibody: Cy3 donkey α-rabbit 711-165-152 (Jackson Immuno 
Research, 1:300) and Sox10 (1’ antibody: sc-17342 (Santa Cruz Biotech, 1:100), 2’ 
antibody: Cy2 Alexa Fluor 488 donkey α-goat 704-546-147 (Jackson Immuno 
Research, 1:300)). Green arrowhead shows Sox10-positive hair follicle bulb 
melanocytes. Red arrowhead points at Sox2-positive dermal papilla (DP) cells (scale 
bar=50um). Hematoxylin and eosin (H&E) staining shows the morphology of hair 
follicles in wt skin (scale bar=200m). Immunolabeling of Tyr::NRasQ61K Ink-/- driven 
hyperplasia (6 month of age) shows Sox10/Sox2 double-positive cells (orange 
arrowhead) as well as Sox10 single positive cells (green arrowhead) (scale 
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bar=50m). H&E staining shows interfollicular ectopic pigmentation (scale 
bar=200m). Primary melanomas present with a bump-like morphology on H&E 
staining with adjacent hyperplasia (scale bar=500m). Orange arrowhead shows 
Sox10/Sox2 double-positive cells and green arrowheads point to Sox10 single-positive 
melanoma cells (scale bar=50m). Lymph nodes are mainly infiltrated by metastatic 
melanoma cells in the border regions (H&E, scale bar=500m). Orange arrowhead 
marks Sox10/Sox2 double-positive cells while green arrowhead points to cells positive 
for Sox10 only (scale bar=50m). (b) Quantification of Sox2 expression during disease 
progression. 0% of Sox10-positive melanocytes were also Sox2-positive in wt 
postnatal murine skin (n=50). On average, 3.2% of hyperplastic cells showed 
Sox10/Sox2 double expression (n=7, total count 3975 cells). In primary melanomas, 
7.8% of all Sox10 positive cells also expressed Sox2 (n=8, total count 3393 cells). 
Lymph node metastases showed on average 16.7% Sox10/Sox2 double positivity 
(n=9, total count: 5110 cells). Data is presented as mean ± s.e.m. P-Values were 
calculated with ANOVA test (hair follicle vs hyperplasia: p = 0.0005; hyperplasia vs 
primary tumor: p = 0.02; primary tumor vs lymph node metastasis: p ≤ 0.001. *p ≤ 0.05, 
***p ≤ 0.001, ****p ≤ 0.0001. (c) Mouse genotypes (control mice lacking the 
Tyr::CreERT2 transgene) and strategy (d) to analyse conditional Sox2 depletion in 
Tyr::NRasQ61K Ink4a-/- mice (non-blinded). (e) Immunostaining of β-Gal (1’ antibody: 
ab9361 (abcam, 1:1000), 2’ antibody: AP194B (Chemicon, 1:250) and 2’ antibody: 
016-030-084 (Jackson Immuno Research, 1:250), developed with TSATM plus Cy3 
amplification kit (Perkin Elmer, 1:100) and Sox2 in Tyr::NRasQ61K Ink4a-/--driven 
hyperplasia. All cells expressing β-Gal (red arrowheads) lack Sox2 expression. The 
green arrowhead marks a Sox2-expressing pigmented cell and is β-Gal-negative 
(scale bar=50m). 3 different recombined hyperplasias and 3 melanomas were 
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analysed; no β-Gal/Sox2-positive cells were detected (not shown). (f) Kaplan-Meier 
curve comparing melanoma-specific survival after conditional Sox2 ablation (Mantel-
Cox test, p=0.96, unpaired t-test). 3-8 month old male and female mice with mixed 
genetic background were used. The sample size was not predetermined by statistical 
methods. 
  
Figure 4. Sox2 is dispensable for tumor growth and metastasis formation. (a) 
Macroscopic picture shows the shaved back skin of a control mouse at 4.5 month of 
age. The white arrowhead marks a primary melanoma, which was further analyzed by 
H&E staining (scale bar=500m). (b) Macroscopic picture shows the shaved back skin 
of a Sox2 cKO mouse at 4.5 month of age. The white arrowhead marks a primary 
melanoma further analyzed by H&E staining (scale bar=500m). (c) Total number of 
primary melanomas (control: n=14, Sox2 cKO: n=13, p=0.56, unpaired t-test). Data is 
presented as mean ± s.e.m. (d) Comparison of recombination efficiency in hyperplasia 
and primary tumors. 50.4% of β-Gal/Sox10 double positive cells were counted in 
hyperplasia (n = 5, total count: 3995 cells) and 49.1% in primary tumors (n = 8, total 
count: 6400 cells, p = 0.92, unpaired t-test). Animals: 4.5-8 month of age, males and 
females, mixed background. Data is presented as mean ± s.e.m. Representative 
picture of primary melanoma immunostained for β-Gal and Sox10 (green arrowheads: 
Sox10-positive cells, orange arrowheads: β-Gal/Sox2 double-positive cells) (scale 
bar=50m). (e) H&E staining shows lung tissue from a control animal with a pigmented 
melanoma metastasis (scale bar=100m). (f) H&E staining shows lung tissue from a 
Sox2 cKO animal with pigmented melanoma metastasis (scale bar=200um). (g) Total 
number of lung metastases (control: n=14, Sox2cKO: n=13, p=0.07, unpaired t-test) 
(h) H&E staining shows liver tissue from a control animal with pigmented melanoma 
metastasis (scale bar=500um). (i) H&E staining shows liver tissue from a Sox2cKO 
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animal with pigmented melanoma metastasis (scale bar=500um). (j) Total number of 
liver metastases (control: n=11, Sox2 cKO: n=12, p=0.30, unpaired t-test). (k) 
Representative picture of a melanoma lung metastasis immunostained for β-Gal and 
Sox10 (orange arrowhead:β-Gal/Sox10-double positive cell (scale bar, 20um). (l) 
Comparison of recombination efficiency in hyperplasia und lung metastases. 50.4 of 
β-Gal/Sox10-double positive cells observed in hyperplasia (n=5, total count 3995 cells) 
and 52.3% in lung metastases (n=13, total count: 438 cells, p=0.91, unpaired t-test). 
Data are presented as mean ± s.e.m. 
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